Exclusive

Publication

Byline

Location

Clinical Trial: Impact of Pharmacist-Led Intervention on Adult Oncology Outpatients

U.S., April 25 -- ClinicalTrials.gov registry received information related to the study (NCT07550478) titled 'Impact of Pharmacist-Led Intervention on Adult Oncology Outpatients' on April 20. Brief S... Read More


Clinical Trial: Repeated Intravenous Thrombolysis for Ischemic Stroke With Medium to Large Vessel Occlusion Presenting Within 4.5 Hours of Onset With Prourokinase

U.S., April 25 -- ClinicalTrials.gov registry received information related to the study (NCT07550296) titled 'Repeated Intravenous Thrombolysis for Ischemic Stroke With Medium to Large Vessel Occlusio... Read More


Singapore Clinical Trial: A multicentre, randomised, double-blind, parallel group, placebo-controlled trial to assess the effects of oral TRPC6 inhibitor BI 764198 taken over a 104 week treatment period in adult and adolescent participants with primary focal segmental glomerulosclerosis (pFSGS) or genetic FSGS related to TRPC6 gene variants

Singapore, April 25 -- The Health Sciences Authority received information related to the study titled 'A multicentre, randomised, double-blind, parallel group, placebo-controlled trial to assess the e... Read More


Singapore Clinical Trial: A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype

Singapore, April 25 -- The Health Sciences Authority received information related to the study titled 'A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investiga... Read More


Singapore Clinical Trial: A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype

Singapore, April 25 -- The Health Sciences Authority received information related to the study titled 'A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investiga... Read More


Clinical Trial: Group Reading and Oral Exercise Program for Older Adults

U.S., April 25 -- ClinicalTrials.gov registry received information related to the study (NCT07550335) titled 'Group Reading and Oral Exercise Program for Older Adults' on April 19. Brief Summary: Dep... Read More


Singapore Clinical Trial: A Phase 1, Randomized, Placebo-Controlled, Single Ascending Dose-Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4167586 in Participants with Obesity or Overweight who are Otherwise Healthy.

Singapore, April 25 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, Randomized, Placebo-Controlled, Single Ascending Dose-Escalation Study to Investigate ... Read More


Singapore Clinical Trial: A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084, Cetuximab, and mFOLFOX6 versus mFOLFOX6 With or Without Bevacizumab as First-line Treatment of Participants With KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer (KANDLELIT-012)

Singapore, April 25 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy... Read More


Clinical Trial: Social Equity Data in Primary Care: How Best to Collect Data From Hard-to-Reach Populations

U.S., April 25 -- ClinicalTrials.gov registry received information related to the study (NCT07550101) titled 'Social Equity Data in Primary Care: How Best to Collect Data From Hard-to-Reach Population... Read More


Singapore Clinical Trial: A Phase III, 52-week, prospective, randomized, double-blind, placebo-controlled, parallel-group, multi-center study, with a primary efficacy endpoint at 12 weeks, to determine the efficacy, safety, and tolerability of fixed doses of 15 mg bid and 30 mg bid of evenamide as add-on in patients with documented treatment-resistant schizophrenia, which is not adequately controlled by a stable therapeutic dose of the patient’s current antipsychotic medication(s).

Singapore, April 25 -- The Health Sciences Authority received information related to the study titled 'A Phase III, 52-week, prospective, randomized, double-blind, placebo-controlled, parallel-group, ... Read More